{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-282637","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.593946+00:00","generated_at":"2026-06-21T22:40:43.015200+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aileron Therapeutics effects 1-for-20 reverse stock split effective Nov 10, 2022","bullets":["Reverse split reduces authorized common shares from 300M to 15M, then tripled to 45M.","No fractional shares issued; stockholders get cash payment for fractional interests.","All outstanding stock options and warrants adjusted per their terms.","Split-adjusted trading begins on Nasdaq at market open on November 11, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-282637","json":"https://secwatch.observer/filing/0001193125-22-282637.json","markdown":"https://secwatch.observer/filing/0001193125-22-282637.md","text":"https://secwatch.observer/filing/0001193125-22-282637.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522282637/0001193125-22-282637-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522282637/d379228d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:40:43.015200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"619e8d774b075ae7c6cc5f94e19c5dc083e79a0d","claim":"Rein Therapeutics, Inc.: Effected a 1-for-20 reverse stock split and reduced authorized common shares from 300,000,000 to 15,000,000 then multiplied by three to 45,000,000 (effective 2022-11-10).","evidence_excerpt":"On November 10, 2022 (the “Effective Date”), Aileron Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which effected, as of 5:00 p.m. Eastern Time on the Effective Date, a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding common stock, $0.001 par value per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522282637/0001193125-22-282637-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2022-11-10"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}